Subretinal Fluid

BARCELONA, Spain — A post hoc analysis of PULSAR trial data showed sustained fluid control at 2 years with fewer injections and longer dosing intervals in patients treated with aflibercept 8 mg for wet age-related macular degeneration.

A 75-year-old man was referred to the retina service by his comprehensive ophthalmologist for high-risk medication monitoring. The patient denied acute ocular symptoms such as vision loss, flashes, floaters or eye pain.

Central serous chorioretinopathy is a common chorioretinal disease characterized by a buildup of subretinal fluid at the macula caused by abnormalities of the retinal pigment epithelium pump dysfunction and choroidal circulation.

Subretinal fluid left over after anti-VEGF treatment may be associated with better best corrected visual acuity, according to a study.

A 39-year-old man presented to the comprehensive ophthalmology service at the New England Eye Center with 6 weeks of daily headaches and blurry vision.

The results of the 2020 Global Trends in Retina Survey reveal a world that is more interconnected and where interactions between groups and individuals in the ophthalmology community increasingly grow across global borders.

Subretinal fluid volatility may play a key role in predicting visual acuity outcomes of neovascular age-related macular degeneration, according to research presented at the virtual American Academy of Ophthalmology annual meeting.

A 20-year-old primigravid woman was admitted to the labor and delivery ward at Tufts Medical Center for monitoring of preeclampsia. She was at 32 weeks of gestation.

Persistent subretinal fluid, or SRF, in the course of anti-VEGF treatment may operate as a compensatory mechanism that maintains the function of the degenerating macula and prevents progression to atrophy, according to one presenter at the virtual Association for Research in Vision and Ophthalmology meeting.